RxDoctor Payments DataLook up a doctor →

Timothy Mullally, DO

Sports Medicine · Crown Point, INNPI 1366462046

Payments from drug & device makers

$12,069in general payments, 2019–2025

Across 774 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$710
  • Amgen$690
  • Pfizer$520
  • plus $5K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)167$2,343
Novo Nordisk96$1,361
AstraZeneca76$1,310
Lilly USA, LLC36$710
Amgen(2 entities)55$690
Pfizer31$520
Takeda Pharmaceuticals U.S.A., Inc.30$460
Otsuka America Pharmaceutical, Inc.19$404
Johnson & Johnson(3 entities)18$306
Esperion Therapeutics, Inc.16$278
Merck21$265
Astellas Pharma US Inc11$264
Abbott20$263
Ironwood Pharmaceuticals, Inc14$211
Antares Pharma, Inc.13$208
Amarin Pharma, Inc.14$185
Boehringer Ingelheim11$179
Corium, LLC8$171
GSK11$162
Novartis10$151
Exact Sciences7$123
Biohaven Pharmaceuticals, Inc.7$115
Bausch Health US, LLC7$114
Lundbeck LLC4$99
Almatica Pharma LLC5$84
Tris Pharma Inc4$74
Organon6$72
Arbor Pharmaceuticals, Inc.5$64
Bioventus LLC3$62
Bayer3$61
Seqirus USA Inc3$56
Sanofi-aventis U.S. LLC4$56
Shire North American Group Inc3$49
Vanda Pharmaceuticals Inc.2$35
Idorsia Pharmaceuticals US Inc2$33
Philips North America LLC2$32
Currax Pharmaceuticals LLC2$30
Axsome Therapeutics, Inc.1$29
Phathom Pharmaceuticals, Inc.2$29
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$28
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$27
Fidia Pharma USA Inc.2$27
Nalpropion Pharmaceuticals LLC2$26
Alfasigma USA, Inc.2$26
Recordati_rare_diseases_inc.1$22
Corcept Therapeutics1$21
Organogenesis Inc.1$20
Halozyme Inc1$20
Phadia US Inc.1$19
Cepheid1$19
Biohaven Pharmaceutical Holding Company Ltd.1$17
Zyla Life Sciences, Inc.1$17
Eisai Inc.1$17
Noven Therapeutics, LLC1$16
DJO, LLC1$16
Dexcom, Inc.1$16
Cranial Technologies, Inc1$14
Kowa Pharmaceuticals America, Inc.1$13
Hydrocision, Inc.1$13
Assertio Therapeutics, Inc.1$13

How this compares

$12,069 in reported general payments places this provider in the 80th percentile of 156 sports medicine providers in Indiana.

See all sports medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$319,645
Medicare patients
664
Services billed
11,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other sports medicine in Crown Point

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →